More Insulin Biosimilars Are Forthcoming; The Market Outlook for Them
During the past few weeks, in both SEC-mandated (for publicly-held companies) earnings reports and investor presentations, plus in the business news and pharmaceutical industry trade press, we received several important, relevant updates on not one, but on FOUR insulin biosimilars currently in development from two different companies. We also know that in addition to them, insulin biosimilars are in development from at least three additional companies, plus as the " innovators " , the traditional " Big Three " insulin-makers of Lilly, Novo Nordisk and Sanofi continue making their bestsellers (for the time being, anyway).&n...
Source: Scott's Web Log - September 12, 2022 Category: Endocrinology Tags: 2022 Biosimilar Biosomilars generic insulin Source Type: blogs
Live the Wheat Belly lifestyle, get off prescription medications
Take a look at the list of medications people have been able to stop by following the Wheat Belly lifestyle.
These represent medications prescribed by doctors to, in effect, “treat” the consequences of consuming wheat and grains. They prescribe drugs to treat inflammation, swelling, skin rashes, gastrointestinal irritation, high blood sugars, airway allergy, joint pain, high blood pressure, leg edema and other abnormal effects caused by wheat and grains.
The list includes anti-inflammatory and pain medication, acid reflux drugs, injectable and oral drugs for diabetes, numerous anti-hypertensive agents, asthma i...
Source: Wheat Belly Blog - October 27, 2018 Category: Cardiology Authors: Dr. Davis Tags: News & Updates autoimmune blood sugar bowel flora cholesterol Gliadin gluten-free grain-free grains Inflammation undoctored Weight Loss wheat belly Source Type: blogs
Winners Announced: RWJF Choosing Care Challenge!
By CHELSEA POLANIECKI
Ever step out of your doctor’s office feeling overwhelmed and instantly forget all of your doctor’s instructions? Instinctively, you look down to your phone to check your texts and emails–wait, no. Instead, you look down to your phone and see that your doctor has asked you to get an X-ray and you need to pick up your Advair prescription. You can see your options for local imaging centers and pharmacies, and what they will cost you, based on your specific insurance plan and location, right on your phone before even getting home. Well, that’s new.
The days of being rushed out of your docto...
Source: The Health Care Blog - July 24, 2017 Category: Consumer Health News Authors: Matthew Holt Tags: Uncategorized Source Type: blogs
MKSAP: 67-year-old man with worsening exertional dyspnea
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 67-year-old man is evaluated for a 6-month history of worsening exertional dyspnea. He has a history of severe COPD diagnosed 4 years ago and previously had minimal exertional symptoms. However, he now notes shortness of breath when walking short distances that is limiting his activity level. He does not have chest pain, gastrointestinal symptoms, or sleep-related symptoms. Medical history is otherwise unremarkable. Medications are a twice-daily fluticasone/salmeterol inhaler and an as-needed albuterol/ipratro...
Source: Kevin, M.D. - Medical Weblog - February 11, 2017 Category: Journals (General) Authors: < a href="http://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > Tags: Conditions Pulmonology Source Type: blogs
Updated Medicare and Medicaid Drug Spending Data Released
On November 15, 2016, the Centers for Medicare and Medicaid Services (CMS) released updated Medicare and Medicaid drug spending data, to include information for calendar year (CY) 2015 through its online interactive dashboards for Medicare and Medicaid. The inclusion of the Medicaid drug spending data on the public dashboard is new this year, as is the addition of high-level (aggregated) Medicare drug rebate data.
CMS noted that “there is significant growth in spending on prescription drugs, representing a significant burden.” In CY 2015, total prescription drug costs amounted to roughly $457 billion – an estimated ...
Source: Policy and Medicine - December 14, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
It’s time to treat mental illness as seriously as we treat heart disease
I saw a patient last week for her chest pain. A 60-year-old woman came into the hospital because her chest tightened every time she went running. The pain would last about 20 minutes, centered on the left side of her chest, and radiated to her left arm. It lasted until she would finally take a break from running and sit down.
“This is classic,” I thought. “Stable angina.” I could now direct my line of questioning for the rest of the medical history to confirm my suspicions. “Any other medical problems? Ever been hospitalized before?”
“Well, I had a heart attack two years ago.”
“OK, any medications?”
“...
Source: Kevin, M.D. - Medical Weblog - March 25, 2016 Category: Journals (General) Authors: Ramin Lalezari Tags: Conditions Psychiatry Source Type: blogs
What medications have you been able to stop on the Wheat Belly lifestyle?
I posed this question on the Wheat Belly Facebook page recently and received an overwhelming response. Here, I share a partial list of the responses: medications people have been able to stop by following the Wheat Belly lifestyle.
Just take a look at this incredible list: these represent medications prescribed by doctors to, in effect, “treat” the consequences of consuming wheat and grains. They prescribe drugs to treat the inflammation, swelling, skin rashes, gastrointestinal irritation, high blood sugars, airway allergy, and other abnormal effects all caused by wheat and grains.
The list includes anti-inf...
Source: Wheat Belly Blog - October 6, 2015 Category: Cardiology Authors: Dr. Davis Tags: Wheat Belly Lifestyle asthma cholesterol diabetes drugs gluten grains hypertension prescription medication reflux Source Type: blogs
GlaxoSmithKline Plans Adjustments To Its Sales Incentive Program
GlaxoSmithKline’s 2012 Corporate Integrity Agreement made mandatory the company’s “Patient First” program (or a “substantially equivalent” program), under which GSK agreed not to provide incentive compensation or discipline to its sales reps based upon the volume of sales of GSK products. This past week, Bloomberg reports that GSK “is considering changes to its compensation model for sales staff.” The company is "looking into 'more comprehensive options to simplify the Patient First program' and will provide a report within a month,” states Bloomberg.
Patient First Program
In 2011, GSK became ...
Source: Policy and Medicine - April 14, 2015 Category: American Health Authors: Thomas Sullivan Source Type: blogs
MKSAP: 72-year-old man with dyspnea at rest
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 72-year-old man is evaluated for dyspnea at rest. He has end-stage COPD and is on a home hospice program. He has weight loss, reduced functional capacity, and muscle atrophy. His medications are ipratropium, salmeterol, fluticasone, albuterol as needed, and prednisone. He is uncomfortable, with chronic air hunger that has gradually increased over the past 2 weeks. Otherwise, his symptoms have been stable without change in cough, sputum production, or fever. Following a physical exam, what is the most appropria...
Source: Kevin, M.D. - Medical Weblog - February 7, 2015 Category: Journals (General) Authors: mksap Tags: Conditions Pulmonology Source Type: blogs
A Year After Making Big Changes To Sales Practices, GSK Cuts R&D In Midst of Declining Sales
GlaxoSmithKline’s 2012 Corporate Integrity Agreement made mandatory the company’s policy that it would not provide sales reps with incentive compensation based upon volume of sales. In December 2013, GSK announced that they would stop paying healthcare professionals to speak at conferences and would abandon prescription sales targets. It turned out this decision was not entirely voluntary—in June of this year, GSK settled under state consumer protection and agreed to promotional restrictions above and beyond their initial CIA.
While some speculated that these announcements might push other companies to adop...
Source: Policy and Medicine - December 19, 2014 Category: American Health Authors: Thomas Sullivan Source Type: blogs
GSK Settles for $105 Million Under State Consumer Protection Laws; Agrees to Unprecedented Compliance Provisions Through 2019
GlaxoSmithKline reached a $105 million settlement with 44 states and D.C. to resolve allegations that the company unlawfully marketed three products—asthma drug Advair, and antidepressant drugs Paxil and Wellbutrin. This settlement is newsworthy for a number of reasons. First, GSK's $3 billion settlement from 2012 involved the same allegations and conduct, brought under the False Claims Act. This $105 million settlement was brought under states' various consumer protection laws, and offers another "bite at the apple" in the sense that GSK has to pay twice for their alleged marketing practices. Second, a number of the set...
Source: Policy and Medicine - June 16, 2014 Category: American Health Authors: Thomas Sullivan Source Type: blogs
Don't mess with Cali Attorney General Kamala D. Harris
SAN FRANCISCO – Attorney General Kamala D. Harris today announced a $105 million multistate settlement with GlaxoSmithKline, LLC (GSK) to resolve allegations that the company unlawfully promoted its asthma drug, Advair, and antidepressant drugs, Paxil and Wellbutrin. California’s portion of the settlement is the largest of any state, at $7,087,897.For the first time in a settlement with a large pharmaceutical manufacturer, GSK is prohibited from providing incentive payments to its salespeople, which serve to encourage off-label promotion of drugs, and from using paid doctors to promote its products.“Patient care is u...
Source: PharmaGossip - June 10, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Tut tut GSK
GlaxoSmithKline (GSK) has confirmed it is going to pay a massive fine after admitting it mis-promoted a range of drugs in the US.The pharmaceutical company stated that it will pay $105 million (£63 million) settlement with 44 US states and the District of Columbia following the way the firm promoted anti-depressants Paxil and Wellbutrin and asthma medication Advair.However, GSK did not admit any wrongdoing regarding the promotion of the medication and insisted that the money it is paying out is in relation to previous issues."We don't feel like this is who we are today," GSK spokeswoman Mary Anne Rhyne told the BBC. "Thes...
Source: PharmaGossip - June 5, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Desperately hunting Madonna
Its ethics questioned, GSK to scrap individual sales targetsLONDON -- British drug company GlaxoSmithKline says it will stop paying doctors to promote its products at speaking engagements and scrap individual sales targets, months after its ethics were challenged by a bribery scandal in China.The group last week announced sweeping changes to its marketing practices, which also included a halt to direct financial support to health care professionals to attend medical conferences. But it left open the possibility of funding through grants."It is patients' interests that always come first," Andrew Witty, the company's chief e...
Source: PharmaGossip - December 22, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
MKSAP: 33-year-old woman with whitish spots in the mouth and throat
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 33-year-old woman is evaluated for a 5-week history of whitish spots in the mouth and the back of the throat and discomfort with swallowing solid foods. This is her first episode of these symptoms. She has had no mouth pain, trouble ingesting liquids or pills, nausea, vomiting, diarrhea, fever, chills, sweats, or skin problems. She has a 3-year history of HIV infection and also has moderately severe asthma, which is now well controlled with inhaled medications that were recently prescribed. Her medications are...
Source: Kevin, M.D. - Medical Weblog - December 1, 2013 Category: Family Physicians Tags: Conditions Infectious disease Source Type: blogs
